You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 124 No. 2, February 1989 TABLE OF CONTENTS
  Archives
  •  Online Features
  PAPERS READ BEFORE THE ANNUAL MEETING OF THE SOCIETY OF SURGICAL ONCOLOGY, NEW ORLEANS, LA, MAY 22 TO MAY 25, 1988-Part II
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on HighWire
 •Citing articles on Web of Science (9)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Prognostic Significance of Cellular Immunity to Autologous Breast Carcinoma and Glycoprotein 55

Maurice M. Black, MD; Reinhard E. Zachrau, MD; Roy H. Ashikari, MD; Benjamin F. Hankey, ScD

Arch Surg. 1989;124(2):202-206.


Abstract

• Using a skin window (SW) procedure, we evaluated postoperative cell-mediated immunity (CMI) to autologous breast cancer with reference to its prognostic significance, the nature of the immunogen, and the therapeutic implications. It appears that SW reactivity to autologous breast cancer is prognostically favorable per se and is independent of the prognostic significance of the nuclear grade of the cancer cells; SW reactivity to autologous breast cancer reflects CMI to a determinant(s) that is expressed by glycoprotein 55, the principal envelope glycoprotein of the RIII-murine mammary tumor virus; the glycoprotein 55-like CMI determinant(s) is more regularly expressed by preinvasive than by invasive breast cancers; tumor antigenicity and host reactivity may vary independently; and postoperative monitoring of CMI to autologous breast cancer is prognostically and therapeutically important.

(Arch Surg 1989;124:202-206)



Author Affiliations

From the Departments of Pathology (Drs Black and Zachrau) and Surgery (Dr Ashikari), New York Medical College, Valhalla, and Surveillance and Operations Research Branch, Division of Cancer Prevention and Control, National Cancer Institute, Bethesda, Md (Dr Hankey).


Footnotes

Accepted for publication Nov 3, 1988.

Read before the Annual Meeting of the Society of Surgical Oncology, New Orleans, May 25, 1988.

Reprint requests to Department of Pathology, New York Medical College, Valhalla, NY 10595 (Dr Black).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Heightened Risk of Breast Cancer Following Pregnancy: Could Lasting Systemic Immune Alterations Contribute?
Shakhar et al.
Cancer Epidemiol. Biomarkers Prev. 2007;16:1082-1086.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1989 American Medical Association. All Rights Reserved.